Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines
Identifieur interne : 000356 ( Ncbi/Merge ); précédent : 000355; suivant : 000357Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines
Auteurs : De-Chu C. Tang ; Jianfeng Zhang ; Haroldo Toro ; Zhongkai Shi ; Kent R. Van KampenSource :
- Expert review of vaccines [ 1476-0584 ] ; 2009.
Abstract
A long-sought goal during the battle against avian influenza is to develop a new generation of vaccines capable of mass immunizing humans as well as poultry (the major source of avian influenza for human infections) in a timely manner. Although administration of the currently licensed influenza vaccine is effective in eliciting protective immunity against seasonal influenza, this approach is associated with a number of insurmountable problems for preventing an avian influenza pandemic. Many of the hurdles may be eliminated by developing new avian influenza vaccines that do not require the propagation of an influenza virus during vaccine production. Replication-competent adenovirus-free adenovirus vectors hold promise as a carrier for influenza virus-free avian influenza vaccines owing to their safety profile and rapid manufacture using cultured suspension cells in a serum-free medium. Simple and efficient mass-immunization protocols, including nasal spray for people and automated
Url:
DOI: 10.1586/erv.09.1
PubMed: 19348562
PubMed Central: 2778197
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000540
- to stream Pmc, to step Curation: 000540
- to stream Pmc, to step Checkpoint: 000A85
Links to Exploration step
PMC:2778197Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines</title>
<author><name sortKey="Tang, De Chu C" sort="Tang, De Chu C" uniqKey="Tang D" first="De-Chu C" last="Tang">De-Chu C. Tang</name>
</author>
<author><name sortKey="Zhang, Jianfeng" sort="Zhang, Jianfeng" uniqKey="Zhang J" first="Jianfeng" last="Zhang">Jianfeng Zhang</name>
</author>
<author><name sortKey="Toro, Haroldo" sort="Toro, Haroldo" uniqKey="Toro H" first="Haroldo" last="Toro">Haroldo Toro</name>
</author>
<author><name sortKey="Shi, Zhongkai" sort="Shi, Zhongkai" uniqKey="Shi Z" first="Zhongkai" last="Shi">Zhongkai Shi</name>
</author>
<author><name sortKey="Van Kampen, Kent R" sort="Van Kampen, Kent R" uniqKey="Van Kampen K" first="Kent R" last="Van Kampen">Kent R. Van Kampen</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">19348562</idno>
<idno type="pmc">2778197</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778197</idno>
<idno type="RBID">PMC:2778197</idno>
<idno type="doi">10.1586/erv.09.1</idno>
<date when="2009">2009</date>
<idno type="wicri:Area/Pmc/Corpus">000540</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000540</idno>
<idno type="wicri:Area/Pmc/Curation">000540</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000540</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000A85</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000A85</idno>
<idno type="wicri:Area/Ncbi/Merge">000356</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines</title>
<author><name sortKey="Tang, De Chu C" sort="Tang, De Chu C" uniqKey="Tang D" first="De-Chu C" last="Tang">De-Chu C. Tang</name>
</author>
<author><name sortKey="Zhang, Jianfeng" sort="Zhang, Jianfeng" uniqKey="Zhang J" first="Jianfeng" last="Zhang">Jianfeng Zhang</name>
</author>
<author><name sortKey="Toro, Haroldo" sort="Toro, Haroldo" uniqKey="Toro H" first="Haroldo" last="Toro">Haroldo Toro</name>
</author>
<author><name sortKey="Shi, Zhongkai" sort="Shi, Zhongkai" uniqKey="Shi Z" first="Zhongkai" last="Shi">Zhongkai Shi</name>
</author>
<author><name sortKey="Van Kampen, Kent R" sort="Van Kampen, Kent R" uniqKey="Van Kampen K" first="Kent R" last="Van Kampen">Kent R. Van Kampen</name>
</author>
</analytic>
<series><title level="j">Expert review of vaccines</title>
<idno type="ISSN">1476-0584</idno>
<idno type="eISSN">1744-8395</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">A long-sought goal during the battle against avian influenza is to develop a new generation of vaccines capable of mass immunizing humans as well as poultry (the major source of avian influenza for human infections) in a timely manner. Although administration of the currently licensed influenza vaccine is effective in eliciting protective immunity against seasonal influenza, this approach is associated with a number of insurmountable problems for preventing an avian influenza pandemic. Many of the hurdles may be eliminated by developing new avian influenza vaccines that do not require the propagation of an influenza virus during vaccine production. Replication-competent adenovirus-free adenovirus vectors hold promise as a carrier for influenza virus-free avian influenza vaccines owing to their safety profile and rapid manufacture using cultured suspension cells in a serum-free medium. Simple and efficient mass-immunization protocols, including nasal spray for people and automated <italic>in ovo</italic>
vaccination for poultry, convey another advantage for this class of vaccines. In contrast to parenteral injection of adenovirus vector, the potency of adenovirus-vectored nasal vaccine is not appreciably interfered by pre-existing immunity to adenovirus.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article" xml:lang="EN"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">101155475</journal-id>
<journal-id journal-id-type="pubmed-jr-id">30416</journal-id>
<journal-id journal-id-type="nlm-ta">Expert Rev Vaccines</journal-id>
<journal-title>Expert review of vaccines</journal-title>
<issn pub-type="ppub">1476-0584</issn>
<issn pub-type="epub">1744-8395</issn>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">19348562</article-id>
<article-id pub-id-type="pmc">2778197</article-id>
<article-id pub-id-type="doi">10.1586/erv.09.1</article-id>
<article-id pub-id-type="manuscript">NIHMS117538</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Tang</surname>
<given-names>De-chu C</given-names>
</name>
<degrees>PhD</degrees>
<role>Founder</role>
<xref ref-type="corresp" rid="cor1">†</xref>
<aff id="A1">Vice President of Research, and Chief Technical Officer, Vaxin Inc., 1500 First Avenue North, Birmingham, AL 35203, USA, Tel.: +1 205 909 3738, Fax: +1 205 307 6503,<email>tang@vaxin.com</email>
</aff>
</contrib>
<contrib contrib-type="author"><name><surname>Zhang</surname>
<given-names>Jianfeng</given-names>
</name>
<degrees>PhD</degrees>
<role>Scientist</role>
<aff id="A2">Vaxin Inc., 1500 First Avenue North, Birmingham, AL 35203, USA, Tel.: +1 205 909 3740, Fax: +1 205 307 6503,<email>zhang@vaxin.com</email>
</aff>
</contrib>
<contrib contrib-type="author"><name><surname>Toro</surname>
<given-names>Haroldo</given-names>
</name>
<degrees>DVM, PhD</degrees>
<role>Professor</role>
<aff id="A3">Department of Pathobiology, Auburn University, 264 Greene Hall, Auburn, AL 36849, USA, Tel.: +1 334 844 2662, Fax: +1 334 844 2652,<email>torohar@vetmed.auburn.edu</email>
</aff>
</contrib>
<contrib contrib-type="author"><name><surname>Shi</surname>
<given-names>Zhongkai</given-names>
</name>
<degrees>MD</degrees>
<role>Scientist</role>
<aff id="A4">Vaxin Inc., 1500 First Avenue North, Birmingham, AL 35203, USA, Tel.: +1 205 909 3751, Fax: +1 205 307 6503,<email>shi@vaxin.com</email>
</aff>
</contrib>
<contrib contrib-type="author"><name><surname>Van Kampen</surname>
<given-names>Kent R</given-names>
</name>
<degrees>DVM, PhD</degrees>
<role>Chief Operating Officer</role>
<aff id="A5">Vaxin Inc., 1500 First Avenue North, Birmingham, AL 35203, USA, Tel.: +1 205 909 3737, Fax: +1 205 307 6503,<email>vankampen@vaxin.com</email>
</aff>
</contrib>
</contrib-group>
<author-notes><corresp id="cor1"><label>†</label>
Author for correspondence, Vaxin Inc., 1500 First Avenue North, Birmingham, AL 35203, USA, Tel.: +1 205 909 3738, Fax: +1 205 307 6503, <email>tang@vaxin.com</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted"><day>18</day>
<month>5</month>
<year>2009</year>
</pub-date>
<pub-date pub-type="ppub"><month>4</month>
<year>2009</year>
</pub-date>
<pub-date pub-type="pmc-release"><day>1</day>
<month>2</month>
<year>2010</year>
</pub-date>
<volume>8</volume>
<issue>4</issue>
<fpage>469</fpage>
<lpage>481</lpage>
<permissions><copyright-statement>© 2009 Expert Reviews Ltd</copyright-statement>
<copyright-year>2009</copyright-year>
</permissions>
<abstract><p id="P1">A long-sought goal during the battle against avian influenza is to develop a new generation of vaccines capable of mass immunizing humans as well as poultry (the major source of avian influenza for human infections) in a timely manner. Although administration of the currently licensed influenza vaccine is effective in eliciting protective immunity against seasonal influenza, this approach is associated with a number of insurmountable problems for preventing an avian influenza pandemic. Many of the hurdles may be eliminated by developing new avian influenza vaccines that do not require the propagation of an influenza virus during vaccine production. Replication-competent adenovirus-free adenovirus vectors hold promise as a carrier for influenza virus-free avian influenza vaccines owing to their safety profile and rapid manufacture using cultured suspension cells in a serum-free medium. Simple and efficient mass-immunization protocols, including nasal spray for people and automated <italic>in ovo</italic>
vaccination for poultry, convey another advantage for this class of vaccines. In contrast to parenteral injection of adenovirus vector, the potency of adenovirus-vectored nasal vaccine is not appreciably interfered by pre-existing immunity to adenovirus.</p>
</abstract>
<kwd-group><kwd>adenovirus</kwd>
<kwd>AdHigh</kwd>
<kwd>avian influenza</kwd>
<kwd>influenza virus-free influenza vaccine</kwd>
<kwd><italic>in ovo</italic>
vaccine</kwd>
<kwd>mass immunization</kwd>
<kwd>nasal vaccine</kwd>
<kwd>RCA</kwd>
</kwd-group>
<contract-num rid="AI1">R44 AI068285-02
||AI</contract-num>
<contract-num rid="AI1">R43 AI068285-01
||AI</contract-num>
<contract-sponsor id="AI1">National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID</contract-sponsor>
</article-meta>
</front>
</pmc>
<affiliations><list></list>
<tree><noCountry><name sortKey="Shi, Zhongkai" sort="Shi, Zhongkai" uniqKey="Shi Z" first="Zhongkai" last="Shi">Zhongkai Shi</name>
<name sortKey="Tang, De Chu C" sort="Tang, De Chu C" uniqKey="Tang D" first="De-Chu C" last="Tang">De-Chu C. Tang</name>
<name sortKey="Toro, Haroldo" sort="Toro, Haroldo" uniqKey="Toro H" first="Haroldo" last="Toro">Haroldo Toro</name>
<name sortKey="Van Kampen, Kent R" sort="Van Kampen, Kent R" uniqKey="Van Kampen K" first="Kent R" last="Van Kampen">Kent R. Van Kampen</name>
<name sortKey="Zhang, Jianfeng" sort="Zhang, Jianfeng" uniqKey="Zhang J" first="Jianfeng" last="Zhang">Jianfeng Zhang</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000356 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000356 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= H2N2V1 |flux= Ncbi |étape= Merge |type= RBID |clé= PMC:2778197 |texte= Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:19348562" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a H2N2V1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |